Valuation dashboard for Atossa Therapeutics, Inc. (ATOS) with P/E N/A, P/B N/A, EV/EBITDA N/A and dividend yield N/A. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen.
Analysis Summary
Balance sheet quality for ATOS: current ratio of 5.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Models
| DCF Fair Value | $4.35 |
| vs Current Price | +79.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ATOS | Atossa Therapeutics, Inc. | $24M | |||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.42 |
| Market Cap | $24M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CGTX · CLNN · COYA · GLSI · IMMX · ONCY · SRZN
Explore sector: Healthcare · Biotechnology
More sections of ATOS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks